Peptides for sleep and recovery: a primer

Sleep is when the body does much of its repair work, and growth hormone (GH) is central to that process. In healthy young men, around 70% of daily GH output occurs during the early part of sleep^[1], timed to coincide with the first episode of slow-wave sleep. This physiology is why ipamorelin and CJC-1295, both of which act on the GH secretagogue axis, have attracted interest from researchers and clinicians working on sleep quality and overnight recovery. The evidence for each differs considerably, and neither is an approved medicine.

The GH-sleep connection: what the research shows

The link between slow-wave sleep and GH release is well established. Van Cauter and colleagues found a linear relationship between the amount of slow-wave sleep and the amount of GH secreted during that window^[1], and the underlying driver is hypothalamic GHRH (growth-hormone-releasing hormone) release. When slow-wave sleep increases, so does GH output. When it is disrupted, GH output falls. The relationship also declines with age: from the fourth decade onward, slow-wave sleep and 24-hour GH secretion both drop together.

This is the mechanistic basis for the claim that GH secretagogues could support sleep and recovery. If a compound raises GH during the overnight window by amplifying the natural GHRH signal, and if GH is doing tissue-repair work during that same window, there is a plausible chain of reasoning. Plausible is not the same as proven, and the human data is where the story gets thinner.

Ipamorelin: selective secretagogue, thin human trial record

Ipamorelin is a synthetic pentapeptide characterised in the late 1990s as the first selective GH secretagogue^[2]. It binds the GHS-R receptor (the growth-hormone secretagogue receptor, the same one that responds to the hunger hormone ghrelin) and triggers a GH pulse. The selectivity claim matters: unlike older secretagogues such as GHRP-2 or GHRP-6, ipamorelin does not meaningfully raise cortisol or prolactin at doses needed to stimulate GH release.

The appeal for overnight use follows from basic pharmacokinetics. Ipamorelin has a short half-life of roughly two hours, meaning a pre-sleep injection would produce a GH pulse during the early sleep window, which is when slow-wave sleep and natural GH release coincide. The pharmacokinetic-pharmacodynamic modelling study in human volunteers confirmed the peak GH response occurs around 40 minutes post-dose with an exponential decline thereafter.

What the human trial record does not contain is an efficacy study. There is no published Phase 2 or Phase 3 trial of ipamorelin for sleep quality, recovery, body composition, or any clinical endpoint. The published human work is pharmacokinetic characterisation, not therapeutic evidence. The 2026 American Journal of Sports Medicine review of injectable peptide therapy concluded that the evidence base does not currently support clinical recommendations for ipamorelin in orthopaedic or sports medicine contexts.

CJC-1295: the long-acting GHRH analogue and the name confusion

CJC-1295 is a GHRH analogue, not a GHS-R agonist. It mimics GHRH itself rather than ghrelin, binding the GHRH receptor at the pituitary to trigger GH release. The clinical research by Teichman and colleagues found that a single injection produced dose-dependent increases in mean plasma GH of two to ten fold for six or more days, with IGF-1 remaining elevated for nine to eleven days^[3]. Ionescu and Frohman showed that GH secretion under CJC-1295 preserved pulsatile rhythm rather than flattening it^[4], with basal trough GH rising by 7.5-fold and overall mean GH by 46%.

Before going further, the naming problem matters. Most grey-market vendors selling 'CJC-1295' are selling CJC-1295 without DAC, a 29-residue peptide identical to MOD-GRF(1-29), which has a half-life of around 30 minutes. The compound studied in those published Teichman and Ionescu papers is CJC-1295 with DAC, which carries an albumin-binding linker and a half-life of roughly six to eight days. The two share a name but not a pharmacokinetic profile. The distinction matters for anyone trying to reconcile marketing claims with published data.

As with ipamorelin, the CJC-1295 clinical programme did not progress beyond early-phase pharmacokinetic studies. The 2026 sports medicine review classified the combination of CJC-1295 and ipamorelin as showing effects only in murine models^[5], with no human data justifying clinical use. Neither compound is authorised by any regulator in the EU, EEA, UK, or US.

What we do not yet know

The mechanistic reasoning is coherent: GH rises during slow-wave sleep, GHRH drives that rise, and both ipamorelin and CJC-1295 act on that axis. But mechanistic plausibility is not clinical evidence. The questions that remain open are substantial: Does pre-sleep ipamorelin or CJC-1295 dosing meaningfully improve slow-wave sleep architecture in humans, or does it simply raise GH without changing sleep quality? Does the GH elevation translate to measurable improvements in tissue repair, strength, or recovery markers? What are the long-term effects of chronic IGF-1 elevation on cancer risk? The theoretical oncology concern that Eric Topol raised in his 2025 Substack piece, grouping these two peptides with tesamorelin as 'growth-hormone-related peptides that carry the potential risk of cancer', cannot be ruled out on current evidence. These are not rhetorical questions. They do not have published answers.

What this means if you are considering either peptide

The interest in ipamorelin and CJC-1295 for sleep and recovery is understandable given the GH-sleep physiology. The evidence trail stops well short of clinical confirmation. Both peptides are unregulated, grey-market products with no quality assurance in the supply chain, WADA-prohibited under section S2, and not approved anywhere. The literature reports dosing ranges in community use, but those ranges are not drawn from efficacy trials and PeptideMethods does not relay them as guidance. See the ipamorelin page and the CJC-1295 page for the full regulatory picture by country. If you are considering either compound, that conversation belongs with a clinician who can weigh your individual history against the gap between the theory and the evidence.